All In Biotech

Drug Trial Radar · NCT02669511

PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Open-label, Non-randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Last checked: Nov 19, 2026Latest source record: Jul 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Nov 12, 2015

Primary completion

Jan 12, 2018

Study completion Jan 12, 2018

Sponsor

Lead sponsor
PIQUR Therapeutics AGIndustry
Sponsor type
Industry
First posted
Feb 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy, safety and pharmacokinetics of PQR309 in patients with relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL).

Conditions

  • Primary Central Nervous System Lymphoma

Interventions

  • PQR309Drug

    Oral PQR309, 80mg or 60mg daily or intermittent dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Every 8 weeks up to 6 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.